NI
GEVA

Numeric Investors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Numeric Investors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-18,335
Closed -$1.26M – 1088
2014
Q3 		$1.26M Buy
+18,335
New +$1.31M 0.02% 393

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors's GEVA Position: Q4 2014 in Review

Numeric Investors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2014, closing a stake of 18,335 shares — an estimated $1.26M sold.

Numeric Investors first reported a position in GEVA in Q3 2014 and held it in 1 quarter. The position peaked at $1.26M in Q3 2014. 126 funds tracked by Wall St. Rank hold GEVA as of Q4 2014.

  • Numeric Investors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • Numeric Investors sold 18,335 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2014, an estimated $1.26M.
  • Numeric Investors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2014 and held it in 1 quarter.
  • Numeric Investors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.26M in Q3 2014.
  • 126 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2014.

Based on Numeric Investors's 13F filing for Q4 2014, filed 6 Feb 2015.